

Application Ser. No.: 10/075,635
Filing Date: February 13, 2002
Examiner: Coleman, Brenda Libby

Remarks

In the Office Action, the Examiner noted that claims 1 to 13 are pending in the application; and that claims 1 to 13 are rejected. By this amendment, claims 1 to 13 have been canceled without prejudice. New claims 14 to 22 have been presented. Thus, claims 14 to 22 are pending in the application. No new subject matter has been inserted through these amendments and all of the new claims 14 to 22 are fully supported by the specification. See, for instance the disclosure at line 25, page 8 to line 5, page 10 of the specification and Example 1 beginning at line 5, page 12 of the specification.

In view of these amendments all of the Examiner's rejections of record are rendered moot.

Conclusions

In view of the above Remarks, it is respectfully submitted that claims 14 to 22 are now in condition for allowance and the early issuance of this case is respectfully requested. In the event the Examiner wishes to contact the undersigned regarding any matter, please call (collect if necessary) the telephone number listed below.

Applicants believe there are no fees due for this Rule 111 Amendment. However, if the Examiner deems that fees are due, please charge these fees to Deposit Account No. 18-1982 for Aventis Pharmaceuticals Inc. Bridgewater, NJ. Please credit any overpayment to Deposit Account No. 18-1982.

Respectfully submitted,

August 4, 2004

Balaram Gupta

Balaram Gupta
Registration No. 40,009
Attorney for Applicants

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
MAIL CODE: BWD-303A
Bridgewater, NJ 08807-0800
Telephone: 908-231-3364
Telefax: 908-231-2626

2501 US CNT

-6 of 6-